MX387839B - Laminina para usarse en el tratamiento de una enfermedad, un trastorno o una afección de un endotelio de córnea. - Google Patents

Laminina para usarse en el tratamiento de una enfermedad, un trastorno o una afección de un endotelio de córnea.

Info

Publication number
MX387839B
MX387839B MX2017005522A MX2017005522A MX387839B MX 387839 B MX387839 B MX 387839B MX 2017005522 A MX2017005522 A MX 2017005522A MX 2017005522 A MX2017005522 A MX 2017005522A MX 387839 B MX387839 B MX 387839B
Authority
MX
Mexico
Prior art keywords
laminin
treatment
disease
disorder
condition
Prior art date
Application number
MX2017005522A
Other languages
English (en)
Other versions
MX2017005522A (es
Inventor
Shigeru Kinoshita
Noriko Koizumi
Naoki Okumura
Original Assignee
Senju Pharma Co
Kyoto Prefectural Public Univ Corp
The Doshisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Pharma Co, Kyoto Prefectural Public Univ Corp, The Doshisha filed Critical Senju Pharma Co
Publication of MX2017005522A publication Critical patent/MX2017005522A/es
Publication of MX387839B publication Critical patent/MX387839B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a una técnica para tratar la córnea; más específicamente, la presente invención es un agente para el tratamiento o la prevención de un estado de la enfermedad endotelial de córnea, el agente incluye por lo menos un factor seleccionado del grupo que consiste en laminina y fragmentos del mismo, en donde el problema se resuelve también al proporcionar una técnica caracterizada porque este agente se administra junto con las células endoteliales de córnea; específicamente, la presente invención puede incluir laminina 511 (a5ß1?1), laminina 521 (a5ß2?1), o un fragmento de éstas.
MX2017005522A 2014-10-31 2015-10-30 Laminina para usarse en el tratamiento de una enfermedad, un trastorno o una afección de un endotelio de córnea. MX387839B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014222947 2014-10-31
PCT/JP2015/005473 WO2016067628A1 (ja) 2014-10-31 2015-10-30 ラミニンによる角膜の新規治療

Publications (2)

Publication Number Publication Date
MX2017005522A MX2017005522A (es) 2017-09-01
MX387839B true MX387839B (es) 2025-03-04

Family

ID=55856992

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005522A MX387839B (es) 2014-10-31 2015-10-30 Laminina para usarse en el tratamiento de una enfermedad, un trastorno o una afección de un endotelio de córnea.

Country Status (9)

Country Link
US (1) US11633477B2 (es)
EP (1) EP3213762B1 (es)
JP (4) JP6925805B2 (es)
CN (2) CN107073067A (es)
BR (1) BR112017008805A2 (es)
CA (1) CA2965770C (es)
MX (1) MX387839B (es)
RU (1) RU2718062C2 (es)
WO (1) WO2016067628A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2763433T3 (es) 2013-11-27 2020-05-28 Kyoto Prefectural Public Univ Corp Aplicación de laminina a cultivos de células endoteliales de la córnea
EP3213761B1 (en) 2014-10-31 2021-05-19 Kyoto Prefectural Public University Corporation Novel treatment of retina using laminin
PT3377637T (pt) * 2016-04-08 2020-06-17 Krystal Biotech Inc Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele
AU2019260757B2 (en) 2018-04-27 2023-09-28 Krystal Biotech, Inc. Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
BR112021014400A2 (pt) 2019-02-08 2021-09-21 Krystal Biotech, Inc. Genoma do vírus do herpes recombinante, vírus do herpes, composição farmacêutica, e, métodos para intensificar, aumentar, elevar e/ou suplementar os níveis de um polipeptídeo cftr em uma ou mais células, para reduzir ou inibir a destruição progressiva do pulmão, para fornecer alívio profilático, paliativo ou terapêutico de um ou mais sinais ou sintomas de fibrose cística e para fornecer alívio profilático, paliativo ou terapêutico de um ou mais sinais ou sintomas de copd
KR102065171B1 (ko) 2019-02-20 2020-01-13 (주)케어젠 대기오염물질에 의한 피부 손상 방지 및 항노화용 펩타이드와 이의 용도
WO2022049328A1 (en) * 2020-09-03 2022-03-10 Stemsight Oy Method for differentiating corneal endothelial cell-like cells from pluripotent stem cells
CA3213789A1 (en) 2021-04-02 2022-10-06 Krystal Biotech, Inc. Viral vectors for cancer therapy
CN116603054A (zh) * 2023-05-17 2023-08-18 山东第一医科大学附属眼科研究所(山东省眼科研究所、山东第一医科大学附属青岛眼科医院) 一种用于角膜内皮修复的药用组合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153593A (en) * 1996-06-05 2000-11-28 The General Hospital Corporation Laminin 5 and the formation of basement membrane structure
US6693169B1 (en) * 1998-10-13 2004-02-17 The General Hospital Corporation Laminin 5, 13 and 14 and uses thereof
EP1177290A2 (en) * 1999-04-30 2002-02-06 Biostratum, Inc. Recombinant laminin 5
US6635616B2 (en) * 2000-05-01 2003-10-21 The General Hospital Corporation Laminin 15
WO2002050111A2 (en) 2000-12-21 2002-06-27 Biostratum, Inc. Isolated laminin 10
CA2443918C (en) 2001-04-11 2012-06-05 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents containing rho kinase inhibitors
JP2003212791A (ja) * 2002-01-17 2003-07-30 Japan Science & Technology Corp ラミニン−６を含む、細胞接着活性及び／又は細胞運動活性調節用組成物
CA2483659A1 (en) 2002-04-30 2003-11-13 Amniotec Inc. Corneal endothelium-like sheet and method of constructing the same
KR20070053152A (ko) * 2003-10-10 2007-05-23 셀룰라 바이오엔지니어링 인코포레이티드 인간의 각막 내피세포 및 각막세포 이식을 위한 세포배양및 수득방법
WO2005037144A2 (en) * 2003-10-10 2005-04-28 Cellular Bioengineering, Inc. Methods and compositions for growing corneal endothelial and related cells on biopolymers and creation of artifical corneal transplants
CN100560142C (zh) 2003-10-10 2009-11-18 细胞生物工程公司 用于在生物聚合物上培养角膜内皮细胞和相关细胞以及产生人工角膜移植物的方法和组合物
EP2438814A3 (en) 2004-01-23 2012-10-03 Advanced Cell Technology, Inc. Improved modalities for the treatment of degenerative diseases of the retina
WO2005087250A1 (en) 2004-02-12 2005-09-22 GOVERNMENT OF THE UNITED STATES OF AMERICA, as respresented by Secretary, Department of Health and Human Services Therapeutic administration of the scrambled anti-angiogenic peptide c16y
JP5255846B2 (ja) * 2006-01-19 2013-08-07 千寿製薬株式会社 生体内で細胞増殖可能な角膜内皮製剤
US20090175835A1 (en) 2006-02-07 2009-07-09 Korea Institute Of Radiological & Medical Sciences Composition for treating damage of central or peripheral nerve system
WO2007127172A2 (en) * 2006-04-27 2007-11-08 The Trustees Of Columbia University In The City Of New York Layered bio-adhesive compositions and uses thereof
KR20220151013A (ko) * 2007-08-29 2022-11-11 센주 세이야꾸 가부시키가이샤 각막 내피 세포 접착 촉진제
US20090306772A1 (en) * 2008-04-18 2009-12-10 The Regents Of The University Of California Ocular Scaffolds and Methods for Subretinal Repair of Bruch's Membrane
US8680182B2 (en) 2009-06-04 2014-03-25 Clemson University Research Foundation Methods for promoting the revascularization and reenervation of CNS lesions
JP5590646B2 (ja) 2009-10-08 2014-09-17 国立大学法人大阪大学 ヒト多能性幹細胞用培養基材およびその利用
RU2418067C1 (ru) 2009-12-03 2011-05-10 Государственное образовательное учреждение высшего профессионального образования "Оренбургский государственный университет" Способ культивирования клеток
WO2011080984A1 (en) 2009-12-29 2011-07-07 Senju Pharmaceutical Co., Ltd. Therapeutic agent (y - 39983 ) for corneal endothelial dysfunction
MX343462B (es) 2010-12-17 2016-11-07 Biolamina Ab Medio del cultivo celular.
JPWO2012173207A1 (ja) 2011-06-14 2015-02-23 独立行政法人理化学研究所 網膜細胞への分化誘導方法
JP5761827B2 (ja) * 2011-07-15 2015-08-12 国立大学法人大阪大学 角膜内皮細胞の調製方法
TW202434266A (zh) * 2011-11-14 2024-09-01 安斯泰來再生醫藥協會 人類rpe細胞之醫藥組合物及其用途
CA3114895A1 (en) 2011-11-25 2013-05-30 Sumitomo Chemical Company, Limited Artificial cell aggregate comprising retinal tissue
JP5985207B2 (ja) 2011-11-25 2016-09-06 住友化学株式会社 網膜色素上皮細胞の製造方法
PL2788472T3 (pl) * 2011-12-06 2019-06-28 Astellas Institute For Regenerative Medicine Sposób ukierunkowanego różnicowania z wytwarzaniem komórek śródbłonka rogówki
WO2013148377A1 (en) * 2012-03-25 2013-10-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating hair growth using truncated laminin-511
PT2925856T (pt) 2012-12-03 2018-06-15 Biolamina Ab Métodos de produção de células epr
SG10201802877WA (en) 2013-10-09 2018-05-30 Healios Kk Method of producing retinal pigment epithelial cell
ES2763433T3 (es) 2013-11-27 2020-05-28 Kyoto Prefectural Public Univ Corp Aplicación de laminina a cultivos de células endoteliales de la córnea
EP3213761B1 (en) 2014-10-31 2021-05-19 Kyoto Prefectural Public University Corporation Novel treatment of retina using laminin
US12403161B2 (en) * 2018-06-29 2025-09-02 Stellular Bio, Inc. Compositions for drug delivery and methods of use thereof

Also Published As

Publication number Publication date
CN113559246A (zh) 2021-10-29
JP2020128434A (ja) 2020-08-27
JP6925805B2 (ja) 2021-08-25
EP3213762B1 (en) 2023-11-29
RU2017118405A3 (es) 2019-05-31
RU2017118405A (ru) 2018-12-03
US20170319693A1 (en) 2017-11-09
JP2024152767A (ja) 2024-10-25
CA2965770C (en) 2024-02-13
BR112017008805A2 (pt) 2017-12-19
CA2965770A1 (en) 2016-05-06
JP2022097730A (ja) 2022-06-30
US11633477B2 (en) 2023-04-25
RU2718062C2 (ru) 2020-03-30
JPWO2016067628A1 (ja) 2017-08-10
WO2016067628A1 (ja) 2016-05-06
EP3213762A1 (en) 2017-09-06
CN107073067A (zh) 2017-08-18
MX2017005522A (es) 2017-09-01
EP3213762A4 (en) 2018-06-06

Similar Documents

Publication Publication Date Title
MX387839B (es) Laminina para usarse en el tratamiento de una enfermedad, un trastorno o una afección de un endotelio de córnea.
MX2024010140A (es) Nuevos metodos.
MX2016000364A (es) Metodos para tratar o prevenir afecciones oftalmologicas.
BR112017002637A2 (pt) métodos para tratar ou prevenir condições oftalmológicas
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
MX2020001774A (es) Composiciones y métodos para tratar enfermedad colestásica.
EA201892431A1 (ru) Олигонуклеотиды для лечения заболевания глаз
PH12017500834A1 (en) Methods and formulations for treating vascular eye diseases
MX382033B (es) Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
MY198928A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
MX2018002723A (es) Macrociclicos peptidomimeticos y usos de los mismos.
EA201890891A1 (ru) Биомаркеры, связанные с заболеваниями, опосредованными интерлейкином-33 (ил-33), и их применение
MX2017005875A (es) Metodos para tratar enfermedades oculares.
AR101740A1 (es) Terapia de combinación y composiciones
MX2017004558A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
MX392677B (es) Composiciones para usarse en el tratamiento de trastornos neurodegenerativos en una población particular de pacientes.
BR112017014361A2 (pt) métodos para aperfeiçoamento de terapia celular
MX392470B (es) Composición farmacéutica que comprende un péptido wt1 para el tratamiento o prevención de una enfermedad angiogénica.
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
UY38352A (es) Inhibidores de integrina alfavbeta6
MX2017002948A (es) Métodos de tratamiento para la sarcoidosis pulmonar.